Al

(redirected from allo)
Also found in: Dictionary, Medical, Financial, Acronyms, Encyclopedia, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for Al

References in periodicals archive ?
ALLO will become a subsidiary of Nelnet and retain its brand identity.
Moline and Jeff Kuenne, Executive Vice President for Network Operations, will continue to lead ALLO and its more than 100 associates.
The first production run of the Allo will be made for the iPhone 5 series and is available to purchase on Kickstarter (https://www.
By adding Allos to existing resellers Learning Well in Scandinavia and EDUTECH in the Middle East, Plateau provides local sales, implementation and support services to companies throughout the EMEA region.
Allos is currently focused on the development and commercialization of FOLOTYN([R]) (pralatrexate injection), a folate analog metabolic inhibitor.
FOLOTYN (pralatrexate injection), a folate analogue metabolic inhibitor, was discovered by Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute and developed by Allos Therapeutics.
Allos Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer.
In accordance with the Agreement and Plan of Merger dated April 4, 2012 among Spectrum, Allos and Sapphire Acquisition Sub, Inc.
SAN DIEGO -- Robbins Geller Rudman & Dowd LLP ("Robbins Geller") today announced that a class action has been commenced in the United States District Court for the District of Colorado on behalf of all persons who held shares of the common stock of Allos Therapeutics, Inc.
Allos is providing the information contained in the press release and conference call as of the date of the release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
Spectrum Pharmaceuticals (NASDAQ:SPPI) today announced that it commenced on Friday, April 13, 2012 a cash tender offer to purchase all of the outstanding shares of common stock of Allos Therapeutics, Inc.
The proposed merger between AMAG and Allos will be submitted to the respective stockholders of AMAG and Allos for their consideration.
July 18 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc.
The Board and shareholders of Allos supported the proposed merger with AMAG based on the strategic rationale, anticipated operating synergies and potential for future growth of the core brands.